Theracos Overview

  • Founded
  • 2000
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $25M
Latest Deal Amount
  • Investors
  • 1

Theracos General Information


Operator of a pharmaceutical research and development company intended to develop novel therapeutic agents for diseases with significant societal impact. The company develops therapeutic agents for diseases with medical need and support pharmaceutical research and development that is directed at improving the standard of care for inflammatory, metabolic or affective disorders, thus enabling healthcare organizations and doctors to provide the right kind of treatment to patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Drug Discovery
Drug Delivery
Primary Office
  • 225 Cedar Hill Street
  • Suite 200
  • Marlborough, MA 01752
  • United States
+1 (508) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Theracos Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 14-Jan-2016 $25M 00000 Completed Profitable
3. Later Stage VC (Series C) 20-Sep-2013 000.00 00000 00000 Completed Profitable
2. Early Stage VC (Series B) 29-Mar-2011 $40M $42.8M 00000 Completed Profitable
1. Early Stage VC (Series A) 04-Jun-2002 $2.77M $2.77M 00.00 Completed Startup
To view Theracos’s complete valuation and funding history, request access »

Theracos Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 000.00 000.00 00 000.00 00.000
Series B 0,000,000 00.000000 00 000 000 00 000 00.000
Series A 2,770,000 $0.001000 8% $1 $1 1x $1 15.25%
To view Theracos’s complete cap table history, request access »

Theracos Executive Team (6)

Name Title Board Seat Contact Info
Albert Collinson Chief Executive Officer, President & Board Member
Andrew Troderman Controller
George Bray MD Member of the Clinical Advisory Board
Ken Fujioka MD Member of the Clinical Advisory Board
Michael Hall JD Secretary to the Board of Directors
You’re viewing 5 of 6 executive team members. Get the full list »

Theracos Board Members (5)

Name Representing Role Since
Albert Collinson Theracos Chief Executive Officer, President & Board Member 000 0000
Jeffrey Bird Ph.D Self Board Member 000 0000
William Smith JD Theracos Board Member 000 0000
You’re viewing 3 of 5 board members. Get the full list »

Theracos Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Theracos Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Jeffrey Bird Angel (individual) Minority 000 0000 000000 0
To view Theracos’s complete investors history, request access »